Ecopamine Injection

Adult dosage

Administer 500 to 1000 mL intravenously daily, corresponding to 50 to 100 g of amino acids.

Children's dosage

For children, the dosage and infusion rate should be adjusted appropriately.

This drug must be used under the direction of a physician and should not be used arbitrarily without the physician's instructions. This drug should not be administered to patients with severely impaired kidney function or elevated blood nitrogen levels. It should also not be given to patients with liver dysfunction, problems in amino acid metabolism, or metabolic disorders that impair nitrogen utilization. It should not be administered to patients with severe heart failure, pulmonary edema, anuria, or acidemia, or those with excessive fluid overload. Care should be taken when administering this drug to patients with congestive heart failure or severe heart failure, patients with edema due to sodium retention, and those with impaired kidney function, as there may be a risk of severe allergic reactions or asthma attacks such as anaphylaxis. This drug contains sulfite components, which may rarely cause allergic reactions; symptoms such as rash, nausea, or vomiting should prompt immediate discontinuation of administration. Cardiac symptoms such as chest discomfort, palpitations, tachycardia, and elevated blood pressure may occur, so any abnormal symptoms should be discussed with healthcare professionals. Rapid or excessive administration of this drug may result in metabolic acidosis due to the body becoming acidic, so care should be taken with the rate and amount of administration. Rarely, serious side effects like chills, fever, headache, respiratory distress, shock, bronchospasm, or urinary spasm may occur. Metabolic complications may include acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, dehydration, hypoglycemia, elevated liver enzymes, vitamin imbalances, electrolyte imbalances, and in children, hyperammonemia. In renal failure patients, blood urea nitrogen (BUN) levels may increase, and blood ammonia levels may fluctuate depending on treatment efficacy. When administering large quantities or using this drug with other electrolyte-containing fluids, special care should be taken to maintain electrolyte balance. Overdosage may lead to metabolic alkalosis; hence caution should be exercised when using acetate ion solutions. For patients with a history of kidney disease, lung disease, or severe heart disease, careful administration should avoid fluid overload. Diabetes patients must have their blood glucose levels monitored frequently to ensure there are no abnormalities. The drug may reduce the protein-sparing effect when used in conjunction with tetracycline antibiotics, so caution is necessary. The safety of this drug in pregnant women has not been sufficiently established, and it should only be used when the therapeutic benefits outweigh the risks. In children, the drug should be administered at lower concentrations due to potentially immature liver function, and blood ammonia levels should be monitored frequently in infants. The elderly may have impaired physical functions, so administration should be done slowly, with dose adjustments as needed, and careful attention should be given. As the drug contains electrolytes, when administered in large quantities or in combination with electrolyte fluids, careful attention to electrolyte balance is necessary. When intravenous infusion is performed, it should be done slowly; rapid infusion can cause chills or vomiting and may significantly increase amino acid loss through the kidneys. At low temperatures, the drug should be warmed to body temperature before use, and strict aseptic conditions should be maintained during preparation and management to reduce infection risk. The solution should not be used if it is turbid, discolored, or leaking and should be used quickly once opened, with refrigeration limited to 24 hours. Care should be taken to prevent damage to the packaging during storage, and products with damaged rubber stopper protective films should not be used.

Serious side effects

• Hives
• difficulty breathing
• asthma attacks
• shock
• bronchospasm.

Mild side effects

• Rash
• nausea
• vomiting
• chest discomfort
• palpitations
• tachycardia
• elevated blood pressure
• chills
• fever
• headache

This drug should be stored in a sealed container to prevent air or moisture from entering and kept at room temperature between 1 degree and 30 degrees Celsius. Proper storage will maintain the drug's efficacy and prevent degradation.

Appearance

Colorless and transparent injection solution contained in a colorless to light yellow clear liquid in a polypropylene aqueous injection container.

Package unit

For intravenous use - 250 milliliters/bag, For intravenous use - 500 milliliters/bag